Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Net Margin (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Net Margin data on record, last reported at 9.04% in Q3 2025.

  • For Q3 2025, Net Margin fell 1210.0% year-over-year to 9.04%; the TTM value through Dec 2025 reached 12.6%, down 3521.0%, while the annual FY2024 figure was 22.61%, 147.0% up from the prior year.
  • Net Margin reached 9.04% in Q3 2025 per AMPH's latest filing, up from 402.24% in the prior quarter.
  • Across five years, Net Margin topped out at 33.43% in Q4 2022 and bottomed at 402.24% in Q1 2025.
  • Average Net Margin over 5 years is 4.49%, with a median of 18.95% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 2256bps in 2021, then plummeted -42770bps in 2025.
  • A 5-year view of Net Margin shows it stood at 16.52% in 2021, then surged by 102bps to 33.43% in 2022, then crashed by -44bps to 18.74% in 2023, then increased by 24bps to 23.26% in 2024, then tumbled by -61bps to 9.04% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 9.04% in Q3 2025, 402.24% in Q1 2025, and 23.26% in Q4 2024.